US2015191704A1PendingUtilityA1

Poxvirus-plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same

44
Assignee: PAOLETTI ENZOPriority: Dec 30, 2013Filed: Dec 19, 2014Published: Jul 9, 2015
Est. expiryDec 30, 2033(~7.4 yrs left)· nominal 20-yr term from priority
Inventors:Enzo PaolettiRandall L. WeinbergScott J. Goebel
A61P 37/00A61P 33/06A61P 37/04A61K 39/015C12N 2710/24034C12N 7/00C12N 2710/24122C12N 2710/24021A61K 2039/5256A61K 39/275C12N 2710/24143C12N 15/86C12N 2710/24134Y02A50/30
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one Plasmodium antigen. The Plasmodium antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. Advantageously the poxvirus contains DNA coding for and expresses Plasmodium antigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. Also, advantageously, the poxvirus is a NYVAC poxvirus. The invention thus also provides an anti-malarial immunogenic or immunological compositions comprising the poxvirus, and methods for inducing an immunogenic or immunological response against malaria or Plasmodium in a mammal comprising administering to the mammal the poxvirus or an immunological or immunogenic composition containing the poxvirus. The mammal can be a human.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. 
     
     
         2 . The poxvirus of  claim 1  that contains and expresses vaccinia host range gene K1L. 
     
     
         3 . The poxvirus of  claim 2  that is engineered to contain and expresses vaccinia host range gene K1L. 
     
     
         4 . The poxvirus of  claim 3  wherein the poxvirus is attenuated as to mammals. 
     
     
         5 . The poxvirus of  claim 4  wherein the poxvirus is a NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. 
     
     
         6 . A method of inducing an immunological response against the antigen, epitope or immunogen in a mammal comprising administering to the mammal the poxvirus of any one of  claims 1 - 5  or an immunological or immunogenic composition containing the poxvirus. 
     
     
         7 . An immunological or immunogenic composition containing the poxvirus of any one of  claims 1 - 5 . 
     
     
         8 . The poxvirus of any one of  claims 1 - 5  wherein the antigen, epitope or immunogen is at least one  Plasmodium  antigen. 
     
     
         9 . The poxvirus of  claim 8  wherein the  Plasmodium  antigen(s), epitope(s) or immunogen(s) comprise SERA, ABR A, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. 
     
     
         10 . The poxvirus of  claim 9  wherein poxvirus contains DNA coding for and expresses  Plasmodium  antigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. 
     
     
         11 . The poxvirus of  claim 10  wherein the poxvirus is a NYVAC poxvirus. 
     
     
         12 . An anti-malarial immunogenic or immunological composition comprising a poxvirus of  claim 8 . 
     
     
         13 . An anti-malarial immunogenic or immunological composition comprising a poxvirus of  claim 9 . 
     
     
         14 . An anti-malarial immunogenic or immunological composition comprising a poxvirus of  claim 10 . 
     
     
         15 . An anti-malarial immunogenic or immunological composition comprising a poxvirus of  claim 11 . 
     
     
         16 . A method for inducing an immunogenic or immunological response against malaria or  Plasmodium  in a mammal comprising administering to the mammal the poxvirus of  claim 8  or an immunological or immunogenic composition containing the poxvirus. 
     
     
         17 . A method for inducing an immunogenic or immunological response against malaria or  Plasmodium  in a mammal comprising administering to the mammal the poxvirus of  claim 9  or an immunological or immunogenic composition containing the poxvirus. 
     
     
         18 . A method for inducing an immunogenic or immunological response against malaria or  Plasmodium  in a mammal comprising administering to the mammal the poxvirus of  claim 10  or an immunological or immunogenic composition containing the poxvirus. 
     
     
         19 . A method for inducing an immunogenic or immunological response against malaria or  Plasmodium  in a mammal comprising administering to the mammal the poxvirus of  claim 11  or an immunological or immunogenic composition containing the poxvirus.

Join the waitlist — get patent alerts

Track US2015191704A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.